** Shares of biotech firm LianBio rise 18.8% to $4.80 in early trading
** Co says it has completed a strategic review and plans to initiate the winding down of its operations, including the sale of drugs in development
** LIAN expects wind-down activities to be completed by the end of 2024
** Expects to reduce its workforce by over 50 full-time employees, or ~50% of its current employee base, in Q1 2024
** Says anticipates complete dissolution during H1 2027
** Up to last close, stock up ~89% in the last 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments